research use only
Cat.No.S3124
|
In vitro |
DMSO
: 87 mg/mL
(200.23 mM)
Ethanol : 20 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 434.5 | Formula | C24H31FO6 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1177-87-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC 39471,Dexamethasone 21-acetate | SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C)O)C)O)F)C | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
interleukin receptor
|
|---|---|
| In vitro |
Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. |
| In vivo |
Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation. Dexamethasone (100 μg/kg) produces a significant decrease 59.2% of BrdU(+) hippocampal progenitor cells in Sprague–Dawley rats. Dexamethasone (100 μg/kg) decreases ERK activation in granule cell layer in Sprague–Dawley rats. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-AKT / AKT GRP78 / GRP94 / pIREα / IREα / peIF2α / eIF2α CHOP BCRP / P-gp / Mrp2 |
|
29436611 |
| Immunofluorescence | GRP78 |
|
24691439 |
| Growth inhibition assay | Cell viability |
|
22719835 |
(data from https://clinicaltrials.gov, updated on 2026-08-14)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07764497 | RECRUITING | Colorectal Adenocarcinoma Metastatic in the Liver; Liver Metastasis Colon Cancer; Liver Metastases From Colorectal Cancer; Liver Metastases of Colorectal Cancer |
Sunnybrook Health Sciences Centre |
2014-07 | PHASE2 |
| NCT07570173 | RECRUITING | B-cell Acute Lymphoblastic Leukemia |
Merck Sharp & Dohme LLC |
2026-05-18 | PHASE2; PHASE3 |
| NCT07624513 | NOT_YET_RECRUITING | Multiple Myeloma |
Dana-Farber Cancer Institute |
2026-06-08 | PHASE3 |
| NCT07748689 | NOT_YET_RECRUITING | Relapsed / Refractory Multiple Myeloma |
Polish Myeloma Consortium |
2026-10 | PHASE2 |
| NCT07728188 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma |
AbbVie |
2026-11-30 | PHASE3 |
| NCT04507412 | RECRUITING | Arthroplasty, Replacement, Shoulder |
Christian Candrian |
2020-09-09 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.